NAD boosters are now sold as capsules, as patches, and as intravenous drips in wellness clinics and med spas, usually at several hundred dollars a session. NPR examined the evidence behind the category this spring and found what most careful reviews find: the underlying biology is real, the animal work is genuinely interesting, and the human trials are small, short and inconsistent.

That gap deserves a plain explanation rather than either enthusiasm or dismissal, because the molecule at the centre of it is not a fad ingredient. It is one of the most fundamental compounds in human metabolism, which is exactly what makes the marketing so persuasive.

From the Lab to the Ledger

Nicotinamide adenine dinucleotide, NAD for short, is a coenzyme that every cell uses to move electrons around during energy production. It is also consumed by repair enzymes that fix DNA damage and by a family of proteins involved in regulating how cells age. Levels measured in tissue decline with age across species. If you put those three facts together, the pitch writes itself: restore the molecule, restore the function.

The trouble sits between the second and third steps. Oral supplements are usually not NAD itself, which is too large to absorb well, but precursors such as nicotinamide riboside or nicotinamide mononucleotide that the body converts. Those precursors do reliably raise NAD levels in blood. What has not been shown is that raising the measurable level produces the outcomes people are buying: more energy, sharper thinking, slower aging. Trials have generally been small, run for weeks to a few months, and used biomarkers rather than clinical endpoints.

The intravenous version is the least supported part of the category and the most expensive. A pilot study published in February in a real-world clinic setting compared intravenous NAD against intravenous nicotinamide riboside in fourteen people across four consecutive infusion days. It is worth reading for what it reveals about tolerability rather than benefit: the NAD group reported moderate to severe gastrointestinal symptoms, raised heart rate and chest pressure, and needed an average of ninety seven minutes per infusion, while the riboside group finished in about thirty seven minutes with minor tingling and cramping. Both appeared safe over thirty days. Fourteen people, no placebo group, in a commercial wellness setting, is a starting point for a trial rather than a result.

There is also a point that rarely makes it into the marketing. These compounds are close relatives of niacin and its derivatives, which have a long clinical history including doses that affect liver enzymes and glucose handling, and long-term use of high-dose precursors in healthy adults has not been studied over the timescales people intend to use them.

Bio-Pipeline Ledger

NAD precursors as a way to raise measurable NAD levels: demonstrated. Oral nicotinamide riboside and nicotinamide mononucleotide reliably increase blood levels in trials. This is the part that works.

NAD supplementation for energy, cognition or slower aging in healthy adults: not established. Human trials are small and short, results are mixed, and no clinical endpoint has been convincingly moved.

Intravenous NAD infusions: the least evidenced and most costly form, with a documented tolerability problem during the infusion itself and no controlled trial support for the claims made about it.

Niacin and nicotinamide in defined medical uses, including pellagra and certain dermatology indications: established and long-standing, and a different thing from longevity dosing.

NAD-related supplements as regulated products: sold as dietary supplements, which means no pre-market approval for efficacy and no routine verification of what the bottle contains. Third-party testing is the only practical check a buyer has.

Preclinical work in mice and other models: extensive and the genuine source of the excitement. It is also where many longevity interventions have stopped.

The Clinical Reality Check

What is established is narrow and real: NAD matters enormously in cell metabolism, tissue levels fall with age, and oral precursors raise blood levels. Nothing in that chain is controversial.

What is overstated is everything after it. A supplement that moves a laboratory value is not the same as a supplement that changes how you feel or how long you stay well, and the studies that would tell the difference have not been run at the size or duration required. An intravenous drip does not improve that evidence, it only raises the price and adds a cannula. Anyone describing NAD infusions as proven anti-aging treatment has gone past what any published trial supports.

The pragmatic position is the dull one. If you are curious and the cost is genuinely discretionary, an oral precursor from a third-party tested brand is a low-risk experiment, and the honest expectation is that you will not be able to tell whether it did anything. If the same money would otherwise go toward sleep, strength training, blood pressure control or a hearing check, those have outcome data behind them that this category does not. It is also worth telling a clinician what you are taking, because supplements interact with medications more often than people expect.